Department of Clinical Science and Education, Södersjukhuset, Internal Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Anatomy and Neurobiology, Medical University of Gdansk, Gdansk, Poland.
Acta Neuropathol Commun. 2018 Feb 23;6(1):14. doi: 10.1186/s40478-018-0517-1.
Recent data suggest that olfactory deficits could represent an early marker and a pathogenic mechanism at the basis of cognitive decline in type 2 diabetes (T2D). However, research is needed to further characterize olfactory deficits in diabetes, their relation to cognitive decline and underlying mechanisms.The aim of this study was to determine whether T2D impairs odour detection, olfactory memory as well as neuroplasticity in two major brain areas responsible for olfaction and odour coding: the main olfactory bulb (MOB) and the piriform cortex (PC), respectively. Dipeptidyl peptidase-4 inhibitors (DPP-4i) are clinically used T2D drugs exerting also beneficial effects in the brain. Therefore, we aimed to determine whether DPP-4i could reverse the potentially detrimental effects of T2D on the olfactory system.Non-diabetic Wistar and T2D Goto-Kakizaki rats, untreated or treated for 16 weeks with the DPP-4i linagliptin, were employed. Odour detection and olfactory memory were assessed by using the block, the habituation-dishabituation and the buried pellet tests. We assessed neuroplasticity in the MOB by quantifying adult neurogenesis and GABAergic inhibitory interneurons positive for calbindin, parvalbumin and carletinin. In the PC, neuroplasticity was assessed by quantifying the same populations of interneurons and a newly identified form of olfactory neuroplasticity mediated by post-mitotic doublecortin (DCX) + immature neurons.We show that T2D dramatically reduced odour detection and olfactory memory. Moreover, T2D decreased neurogenesis in the MOB, impaired the differentiation of DCX+ immature neurons in the PC and altered GABAergic interneurons protein expression in both olfactory areas. DPP-4i did not improve odour detection and olfactory memory. However, it normalized T2D-induced effects on neuroplasticity.The results provide new knowledge on the detrimental effects of T2D on the olfactory system. This knowledge could constitute essentials for understanding the interplay between T2D and cognitive decline and for designing effective preventive therapies.
最近的数据表明,嗅觉缺陷可能代表 2 型糖尿病(T2D)认知能力下降的早期标志物和致病机制。然而,需要进一步研究来描述糖尿病患者的嗅觉缺陷,以及它们与认知能力下降的关系和潜在机制。本研究旨在确定 T2D 是否会损害两个主要负责嗅觉和气味编码的大脑区域:嗅球(MOB)和梨状皮层(PC)中的气味检测、嗅觉记忆以及神经可塑性。二肽基肽酶-4 抑制剂(DPP-4i)是临床上用于治疗 T2D 的药物,对大脑也有有益的影响。因此,我们旨在确定 DPP-4i 是否可以逆转 T2D 对嗅觉系统的潜在有害影响。未患糖尿病的 Wistar 和 T2D Goto-Kakizaki 大鼠,未经治疗或用 DPP-4i 利拉格列汀治疗 16 周后,用于进行研究。使用阻断、习惯化-去习惯化和埋藏颗粒测试评估气味检测和嗅觉记忆。通过定量分析成年神经发生和钙结合蛋白、钙调蛋白、巴胺 D2 型受体(D2R)阳性的 GABA 能抑制性中间神经元,评估 MOB 中的神经可塑性。在 PC 中,通过定量分析相同的中间神经元群体和一种新发现的由有丝分裂后双皮质素(DCX)+未成熟神经元介导的嗅觉神经可塑性,评估神经可塑性。结果表明,T2D 显著降低了气味检测和嗅觉记忆。此外,T2D 降低了 MOB 中的神经发生,损害了 PC 中 DCX+未成熟神经元的分化,并改变了两个嗅觉区域的 GABA 能中间神经元蛋白表达。DPP-4i 不能改善气味检测和嗅觉记忆。然而,它使 T2D 引起的神经可塑性变化正常化。研究结果提供了关于 T2D 对嗅觉系统的有害影响的新知识。这些知识可能是理解 T2D 和认知能力下降之间相互作用以及设计有效预防疗法的基础。